Company intelligence / Profile preview

Fujian Suncadia Pharmaceuticals

Ownership: Private
Development stage: Other

Overview

Fujian Suncadia Pharmaceuticals develops innovative drugs and specialty infusions for anti-infection and anesthesia. Its lead program HR‑20013 has reached NDA/BLA stage for chemotherapy-induced nausea and vomiting. Other assets are in Phase 3 or Phase 2 clinical trials targeting sleep apnea, chronic hepatitis B, vomiting, and candidemia. The company operates as a research transformation and production base for innovative drugs within the Jiangsu Hengrui Medicine group.

Therapeutic areas: Infectious DiseasesGastroenterologyPulmonologyOncology
Modalities: Small molecule drugSynthetic peptideChemical drugs
Industry: Pharma

Beyond the preview

Go deeper on Fujian Suncadia Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fujian Suncadia Pharmaceuticals.

Explore the full profile